{
    "nctId": "NCT02406885",
    "officialTitle": "APB Study: Apixaban Pharmacokinetics in Bariatric Patients",
    "inclusionCriteria": "* Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB)\n* Signed written informed consent\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\n* Women must not be breastfeeding\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* History of documented clotting/coagulation disorder\n* History of cancer (within the last year)\n* Any diagnosis requiring anti-coagulation\n* History of hypersensitivity reaction to apixaban\n* Active clinically significant bleeding\n* Creatinine \\> 1.5 mg/dL\n* Participants currently receiving any type of anticoagulation or blood thinning medications, including heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS\n* Participant who is taking any of the excluded medications\n\n  * Combined P-glycoprotein and strong cytochrome P450 (CYP) 3A4 inhibitor\n  * Combined P-glycoprotein and moderate CYP 3A4 inhibitor\n  * Combined P-glycoprotein inducer and strong CYP 3A4 inducer\n  * Inducers of p-glycoprotein\n  * Strong inducers of CYP 3A4"
}